Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver [0.03%]
克服中心β-片层#6 (Cβ6) ALK突变（L1256F）、TP53突变以及EML4-ALK v3/b和v5a/b剪接变异体的短形式是重新构想的第五代(5G) ALK TKI必须达到的未满足需求
Alexandria T M Lee,Sai-Hong Ignatius Ou
Alexandria T M Lee
Despite the development and approval of seven anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) spanning over three "generations" since the discovery of ALK fusion positive (ALK+) non-small cell lung cancer (NSCLC), there r...
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu's Approach [0.03%]
Lu氏方法在视频辅助胸腔镜手术中的创新技术
Baofeng Wang,Jiang Wang,Tongyu Sun et al.
Baofeng Wang et al.
Purpose: Lu's approach for video-assisted thoracoscopic surgery (LVATS), which derives from Uniportal Video-Assisted Thoracoscopic Surgery(UVATS), is a novel surgical approach for VATS and carries out micro-innovation for...
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact [0.03%]
最后一根稻草？：分析KEYNOTE-789临床试验的影响
Zhaohui Liao Arter,Misako Nagasaka
Zhaohui Liao Arter
Targeted therapies, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), have revolutionized the treatment landscape for EGFR-mutant non-small cell lung cancer (NSCLC). However, the emergence of resistance to E...
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? [0.03%]
ⅠB~ⅢA期NSCLC完全切除术后单用帕博利珠单抗辅助治疗适应证的解读：FDA批准PEARLS/KEYNOTE-091研究方案吗？
Misako Nagasaka,Saihong Ignatius Ou
Misako Nagasaka
One of the most recent advancements in NSCLC was the approval of immunotherapy in the adjuvant setting. Both atezolizumab and pembrolizumab have been approved for the use in early stage NSCLC patients post resection. As it broadens the opti...
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer [0.03%]
晚期非小细胞肺癌肿瘤相关中性粒细胞的单细胞测序分析
Jinpeng Shi,Jiayu Li,Haowei Wang et al.
Jinpeng Shi et al.
Purpose: Neutrophils act as a non-negligible regulator in the initiation and progression of malignancies, playing bifacial roles in the process. Thus, to understand the heterogeneity of tumor-associated neutrophils (TANs)...
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib [0.03%]
EGFR S645C和EGFR L858R共突变导致肺癌腺癌患者对奥希替尼产生原发耐药性
Li Wang,Fei Quan,Zhen Guo et al.
Li Wang et al.
Approximately 10-20% of patients demonstrate primary resistance to EGFR-TKIs, and different EGFR mutations vary in sensitivity to EGFR-TKIs. We report a case of a 78-year-old male with lung adenocarcinoma that EGFR L858R (AF = 1.32%) coexis...
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia [0.03%]
ALECTUS五年研究结果更新：阿来替尼600 mg Bid与lorlatinib相当（亚洲患者数据）
Alexandria T M Lee,Saihong Ignatius Ou
Alexandria T M Lee
Alectinib, a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), has demonstrated superior progression-free survival over crizotinib with both 300 mg twice daily (J-ALEX) or 600 mg twice daily (ALEX, ALESIA) do...
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? [0.03%]
关于西米普利单抗NSCLC（来自EMPOWER-Lung 1和-Lung 3）FDA适应症中除了EGFR突变和ALK融合外的ROS1融合排除条款。免疫治疗在无吸烟史患者为主且携带可操作驱动基因突变的NSCLC中的最新科学观点更新？
Danielle Brazel,Saihong Ignatius Ou
Danielle Brazel
Cemiplimab is one of seven immune checkpoint inhibitors (ICIs) approved for the first-line (1L) treatment of advanced NSCLC in the US based on EMPOWER-Lung 1 and -Lung 3 trials. In addition to exclusion of NSCLC patients harboring EGFR muta...
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting [0.03%]
从ASCEND-5到ALUR再到ALTA-3：克唑替尼耐药后新一代ALK酪氨酸激酶抑制剂Ⅲ期随机对照临床试验的没落
Alexandria T M Lee,Saihong Ignatius Ou
Alexandria T M Lee
The competing roles of various next-generation ALK TKIs in the first and second line treatment setting of advanced ALK+ NSCLC were based on many phase 3 clinical trials in both the first-line and crizotinib-refractory settings. The approval...
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer [0.03%]
术前同步放化疗后III期非小细胞肺癌淋巴细胞减少对肿瘤反应及预后的相关性分析
Jared Deck,Marissa Hartley,Mohammad Akhter et al.
Jared Deck et al.
Background: Prior studies suggest lymphopenia, systemic immune-inflammatory index, and tumor response all impact clinical outcomes in Stage III NSCLC. We hypothesized that tumor response after CRT would be associated with...